Statins Explained: Atorvastatin, Simvastatin, Rosuvastatin & More
Statins are the most widely prescribed class of drugs in the United States. Atorvastatin alone has held the title of the world's best-selling medication for long stretches of its commercial life. Yet a remarkable number of patients taking them daily have only a vague sense of how they work, why their LDL number matters, or what the muscle aches some people develop actually mean. This guide covers all of it.
How Statins Work: Blocking the Cholesterol Factory
Your liver manufactures most of the cholesterol in your body — dietary intake accounts for only about 20–25% of the total. The rate-limiting step in cholesterol synthesis is catalyzed by an enzyme called HMG-CoA reductase (3-hydroxy-3-methylglutaryl-CoA reductase). Statins are competitive inhibitors of this enzyme. Block HMG-CoA reductase, and the liver produces less cholesterol. In response, liver cells upregulate their expression of LDL receptors — proteins on the cell surface that pull LDL particles out of the bloodstream. The net effect: circulating LDL-cholesterol drops, typically by 30–55% depending on the specific statin and dose.
Why LDL Reduction Matters
LDL particles are the primary vehicle for transporting cholesterol from the liver to peripheral tissues. When LDL circulates in excess, it infiltrates the walls of arteries, gets oxidized, and triggers an inflammatory response. Macrophages engulf the oxidized LDL and become "foam cells" — the precursors of atherosclerotic plaque. Over decades, plaque accumulates, arteries narrow, and the risk of heart attack and stroke rises. When plaque ruptures suddenly, it triggers the clotting cascade that causes the majority of myocardial infarctions.
Large meta-analyses of statin trials — covering more than 170,000 patients — show that each 1 mmol/L (roughly 39 mg/dL) reduction in LDL-cholesterol reduces the relative risk of major cardiovascular events by approximately 22%. In high-risk patients, that translates to a substantial absolute risk reduction over 5 years.
The Statin Potency Ladder
Not all statins are created equal. The AHA/ACC classifies them into three intensity tiers based on expected LDL reduction:
| Intensity | Statins | LDL Reduction | Grapefruit Risk |
|---|---|---|---|
| Low-intensity | Pravastatin 10–20 mg, Fluvastatin 20–40 mg, Lovastatin 20 mg | <30% | Low (pravastatin, fluvastatin) |
| Moderate-intensity | Simvastatin 20–40 mg, Pravastatin 40–80 mg, Atorvastatin 10–20 mg, Lovastatin 40 mg | 30–49% | Yes (simvastatin, lovastatin) |
| High-intensity | Atorvastatin 40–80 mg, Rosuvastatin 20–40 mg | ≥50% | Moderate (atorvastatin) |
Who Should Take a Statin?
The 2019 AHA/ACC guidelines identify four groups for whom statin therapy is clearly beneficial:
- LDL ≥190 mg/dL — likely familial hypercholesterolemia; high-intensity statin indicated regardless of calculated risk.
- Established atherosclerotic cardiovascular disease (ASCVD) — prior heart attack, stroke, TIA, peripheral artery disease, or coronary stenting. High-intensity statin is standard of care.
- Diabetes, age 40–75 — at least moderate-intensity statin, with high-intensity if 10-year risk exceeds 7.5%.
- Primary prevention, 10-year ASCVD risk ≥7.5% — calculated using the Pooled Cohort Equations, factoring in age, sex, race, blood pressure, smoking, and cholesterol values.
Side Effects: What's Real and What's Overstated
Myopathy and myalgia
Muscle aches are the most commonly reported side effect and the most common reason patients stop their statin. Population-level studies suggest about 5–10% of statin users report muscle symptoms, though randomized controlled trial data — where patients don't know whether they're taking a statin or placebo — yields a much lower rate, suggesting a significant "nocebo" effect (side effects from the expectation of side effects). True statin-induced myopathy involves measurable creatine kinase (CK) elevation, and ranges from mild ache to a serious condition. Switching to a lower-intensity statin or a different agent (pravastatin and rosuvastatin have less muscle penetration than simvastatin) resolves symptoms in most cases.
Rhabdomyolysis
RHABDOMYOLYSIS IS RARE BUT SERIOUS. It occurs when severe muscle breakdown releases myoglobin into the bloodstream, which can clog the kidney tubules and cause acute renal failure. Warning signs: severe, diffuse muscle pain and weakness; dark brown or tea-colored urine. If you experience these symptoms while on a statin, stop the medication and seek emergency care immediately. Risk is highest with simvastatin at high doses and with concurrent use of fibrates (gemfibrozil) or certain macrolide antibiotics that raise statin blood levels.
Liver enzyme elevation
Statins can cause transaminase elevation (ALT, AST), usually mild and transient. The old recommendation for routine liver function monitoring has been abandoned by most guidelines; clinically significant hepatotoxicity from statins is rare. A baseline LFT is reasonable; repeat testing is warranted only if symptoms develop.
New-onset diabetes
High-intensity statins modestly increase the risk of developing type 2 diabetes — approximately one additional case per 255 patients treated for 4 years. In patients who already have multiple diabetes risk factors, this is worth discussing. The cardiovascular benefit in high-risk populations still clearly outweighs this risk in most analyses.
The grapefruit interaction
Grapefruit contains furanocoumarins that irreversibly inhibit CYP3A4, the intestinal enzyme that metabolizes simvastatin, lovastatin, and — to a lesser degree — atorvastatin. Inhibiting CYP3A4 raises statin blood levels, increasing the risk of myopathy. A single glass of grapefruit juice can inhibit intestinal CYP3A4 for over 24 hours. Pravastatin and rosuvastatin are not metabolized by CYP3A4 and are not affected by grapefruit.
CoQ10 and memory: the controversies
Statins inhibit the same mevalonate pathway that produces coenzyme Q10, leading to the hypothesis that CoQ10 supplementation might reduce statin-related muscle symptoms. Clinical trial evidence is mixed and not convincing at this point. The FDA added a label warning about memory and cognitive effects after receiving case reports, but subsequent prospective studies — including large randomized trials — have not found a meaningful causal link. The available evidence does not support stopping statin therapy over cognitive concerns without discussion with a physician.
Frequently Asked Questions
How do statins reduce cholesterol?
Statins inhibit HMG-CoA reductase, the rate-limiting enzyme in the liver's cholesterol synthesis pathway. By blocking this enzyme, statins reduce the amount of cholesterol the liver produces internally. In response, liver cells upregulate LDL receptors on their surfaces to pull more LDL cholesterol from the bloodstream to compensate for the reduced internal supply. The result is lower circulating LDL cholesterol — the primary driver of atherosclerosis and cardiovascular risk.
Do statins reduce heart attack risk beyond just lowering cholesterol?
Yes. Statins have "pleiotropic" effects — benefits beyond LDL reduction — that are well-documented and contribute to their impressive cardiovascular outcomes in clinical trials. These include anti-inflammatory effects (lowering hsCRP), stabilization of existing arterial plaques (making them less likely to rupture and cause a heart attack), improvements in endothelial function, and potential antithrombotic effects. These additional mechanisms help explain why statin benefits in cardiovascular outcomes appear larger than what LDL reduction alone would predict.
Do statins cause muscle damage?
Muscle-related side effects are the most commonly reported statin concern. Mild muscle aching (myalgia) affects some patients, particularly at higher doses, and often improves with a switch to a different statin or dose reduction. More serious muscle damage — myositis (elevated creatine kinase with symptoms) and rhabdomyolysis (severe muscle breakdown) — are rare but documented. The risk of serious muscle damage increases when statins are combined with certain drugs, particularly fibrates like gemfibrozil. Reporting new or unexplained muscle pain to your prescriber is always appropriate.
Can you stop taking statins once your cholesterol is under control?
For patients on statins for primary prevention who achieve their cholesterol targets, the question of whether to continue is nuanced and depends on overall cardiovascular risk. For patients with established cardiovascular disease (heart attack, stroke, coronary artery disease), statins are generally continued long-term because the risk reduction persists only as long as the medication is taken. Stopping statins after a cardiovascular event is associated with increased risk of recurrent events. Any changes should be made in consultation with a prescribing clinician.
Concerned about statin side effects or interactions with your other medications? PillID's side effects tool covers the full statin class.
Explore Side Effects